The company believes that innovation is key to improving health outcomes in countries with high disease burdens and weak or fractured healthcare systems. Diagnostic self-testing and community screening programs are seen by many experts as critical tools in achieving global targets for halting the spread of infection disease. This is particularly true for those most at risk in the global health community, many of whom have limited access to facility-based testing services.
Atomo has developed easy-to-use rapid diagnostic test (RDT) platforms ideally suited for deployment in challenging and resource-poor regions, where cost effectiveness, robustness, and usability are central to the success of point of care testing programs.
Atomo has worked closely with frontline healthcare workers in Africa to understand the usability challenges and in-field limitations of standard RDT kits. Insights gleaned have been key to improved development of Atomo’s all-in-one RDT platform technologies, with their focus on improved safety, ease-of-use, and mitigation of user errors.
Atomo is proud to have been supported by the Global Health Investment Fund (GHIF) to develop its HIV at-home and point of care tests.
GHIF is a social impact investment fund established to advance the development of drugs, vaccines, and diagnostics for diseases that disproportionately burden low- and middle-income countries. Backed by donors and institutions that include the Bill & Melinda Gates Foundation, Grand Challenges Canada, and JPMorgan Chase & Co, GHIF investments support product development and innovations that will have significant impact on public health in developing countries.